Processa Pharmaceuticals, Inc. PCSA PHARMA
Company Overview
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Why Investors Should Care
Trades at a P/E of 3.3, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -62.11% |
| 6 Months: | -22.86% |
| 3 Months: | -10.74% |
| 1 Month: | -15.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.76 · Neutral
P/E of 3.32 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PCSA Processa Pharmaceuticals, Inc. PHARMA | 2.16 | 3.32 | $6.03M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 0 | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 42.64K | 27.33K | 12.79K | 9.03K | 15.55K | 5.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.85M | 3.95M | 3.49M | 3.70M | 3.33M |
| Operating Income | - | - | - | - | - | - | - | - | - | -233.94K | -280.33K | -712.85K | - | -1.29M | -1.43M | -1.06M | -882.52K | -1.14M | -1.00M | -986.12K | -801.99K | -2.96M | -2.19M | -3.46M | -3.11M | -3.23M | -5.17M | -6.06M | -4.11M | -2.71M | -2.17M | -2.81M | -3.08M | -3.42M | - | -2.85M | -3.95M | -3.49M | -3.70M | -3.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.85M | -3.95M | -3.49M | -3.70M | -3.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.83M | -3.93M | -3.44M | -3.36M | -3.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 0 |
| Net Income | -851.22K | -791.95K | -644.61K | -2.05M | -295.74K | -280.95K | -574.41K | -827.37K | -234.34K | -232.44K | -278.44K | -711.57K | -633.86K | -1.10M | -1.21M | -852.82K | -750.83K | -969.08K | -863.52K | -874.34K | -733.41K | -3.07M | -2.10M | -3.16M | -2.99M | -3.23M | -5.16M | -6.02M | -4.02M | -2.61M | -2.08M | -2.73M | -3.01M | -3.38M | - | -2.83M | -3.93M | -3.44M | -3.36M | -3.38M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.32 | -0.37 | -3.53 | -1.94 | -1.54 | -1.11 | -1.01 | -1.03 | - | -7.58 | -6.25 | -1.75 | - | -1.29 |
| R&D Expense | 68.50K | 11.73K | 11.74K | 10.79K | 1.71K | - | 5.70K | 574 | - | 139.92K | 160.87K | 457.63K | - | 821.39K | 1.08M | 611.61K | 484.75K | 726.90K | 584.98K | 501.77K | 427.11K | 532.59K | 1.48M | - | - | 2.04M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192.15K | 312.48K | 107.24K | 113.42K | 5.00K | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 58.89K | 124.48K | 40.41K | -12.45K | 5.00K | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 20.26M | 11.46M | 12.05M | 13.99M |
| Operating Income | - | - | - | - | -1.92M | -1.80M | -4.52M | -3.94M | -15.14M | - | -20.26M | -11.46M | -12.05M | -13.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -19.47M | -11.46M | -12.05M | -13.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 362 | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -27.42M | -11.12M | -11.85M | -13.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -530.61K | 0 | 0 | - | 0 |
| Net Income | -2.44M | -3.07M | -4.53M | -3.35M | -1.92M | -1.86M | -3.77M | -3.36M | -14.41M | - | -27.42M | -11.12M | -11.85M | -13.56M |
| Diluted EPS | - | - | - | - | -0.07 | -0.06 | - | - | - | - | -851.25 | -212.00 | -96.78 | -10.36 |
| R&D Expense | 448.03K | 267.06K | 178.09K | 29.25K | 1.54M | 964.16K | 3.09M | 2.32M | 3.17M | 6.88M | 11.49M | 5.80M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.88M | 2.94M | 2.55M | 104.32K | 2.36M | 2.98M | 12.48M | 10.88M | 25.21M | - | 8.62M | 5.79M | 3.23M | 7.81M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 8.39M | 5.63M | 1.88M | 5.67M |
| Cash & Equivalents | 2.79M | 1.02M | 186.86K | 21.23K | 2.09K | 1.07M | 2.85M | 1.74M | 691.54K | 15.42M | - | 6.50M | 4.71M | 1.19M | 5.54M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 70.27K | 0 | - | - | - |
| Total Liabilities | - | 1.32M | 1.27M | 1.34M | 2.08M | 97.69K | 2.61M | 2.78M | 2.87M | 2.27M | - | 1.15M | 797.48K | 1.53M | 2.24M |
| Current Liabilities | - | 715.65K | 1.12M | 843.86K | 2.08M | 97.69K | 2.60M | 645.70K | 1.19M | 1.22M | - | 998.56K | 730.58K | 1.53M | 2.24M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 229.45K | 150.55K | 73.51K | 0 |
| Total Equity | - | 2.56M | 1.67M | 1.21M | -85.70K | -2.27M | 373.16K | 9.70M | 8.01M | 22.94M | - | 7.47M | 4.99M | 1.70M | 5.58M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 32.27K | 51.64K | 148.31K | 2.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.89M | -2.54M | -2.69M | -871.91K | -2.16M | -1.65M | -3.71M | -2.75M | -3.14M | - | -9.61M | -8.06M | -11.25M | -11.39M |
| Investing Cash Flow | -334.34K | -27.67K | -44.94K | 40.20K | -1.04M | 1.00M | -22.28K | - | - | - | 0 | -2.78K | -3.24K | -850.00K |
| Financing Cash Flow | 453.38K | 1.73M | 2.57M | 821.10K | 4.27M | 2.43M | 2.62M | 1.70M | 17.87M | - | -388.84K | 6.27M | 7.73M | 16.58M |
| Capital Expenditure | -334.34K | -27.67K | -11.01K | -1.40K | -23.77K | -20.62K | - | - | - | - | - | -2.78K | -3.24K | -850.00K |
| Free Cash Flow | -2.23M | -2.57M | -2.70M | -873.30K | -2.18M | -1.68M | - | - | - | - | -9.61M | -8.07M | -11.25M | -12.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -9.99M | -1.80M | -3.51M | 4.35M |
| Dividends Paid | - | - | 45.59K | 42.94K | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.6% | 39.8% | 37.7% | -11.0% | 100.0% | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -38,430.4% | - | - | - | - | - | - | - | - | - |
| Net Margin % | -1,270.2% | -982.0% | -4,220.7% | -2,957.2% | -38,341.3% | - | - | - | - | - | - | - | - | - |
| ROE % | -95.2% | -183.7% | -374.7% | 3,913.7% | 84.6% | -497.5% | -38.8% | -41.9% | -62.8% | - | -367.1% | -222.9% | -698.6% | -243.2% |
| ROCE % | - | - | - | - | -84.8% | -470.5% | -38.2% | -40.6% | -63.1% | - | -265.8% | -226.6% | -710.3% | -250.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Connective Capital Management LLC | 3.08% | 85.27K | $167.14K |
| 2 | Stonepine Capital Management, LLC | 1.99% | 55.00K | $107.80K |
| 3 | Geode Capital Management, LLC | 0.80% | 22.09K | $43.30K |
| 4 | Citadel Advisors Llc | 0.77% | 21.31K | $41.76K |
| 5 | Xtx Topco Ltd | 0.48% | 13.29K | $26.05K |
| 6 | Jane Street Group, LLC | 0.48% | 13.26K | $26.00K |
| 7 | Vanguard Capital Management LLC | 0.46% | 12.73K | $24.95K |
| 8 | Stonex Group Inc. | 0.41% | 11.44K | $22.42K |
| 9 | Vanguard Fiduciary Trust Co | 0.39% | 10.86K | $21.28K |
| 10 | UBS Group AG | 0.28% | 7.79K | $15.28K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PCSA
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOYXc3X3Q1TGZaYXQzY0xUQzZFRHZISnF2ZU1udXNRa20yemluM0JOX0ZLNDZMbGFrTnRVLWN1ZnhEV2NXbF9zbVZDZ3VBcEs5ZVNKbXIxeWM5ZDNpZ0ZSN3J6NlBhbWxTdFBhM0lOY0FOaEdTcWR3UEdHMW1GaFVsOVdRbjBIbmJ2MUFaNj…
$PCSA stock is down 34% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOZ3c1OEQ1VWZtRnMwdGMwZVh3NlNBUWNjaFM0enFfUDFDR25lWGstejVveC1FSFhsWmp4cWRMcld2M1hIOUx2a0ZtSDhGYU5OdHJEc09rdWpBUnpPajhpX2dlM0Q5UDM1NlA2YzRMNWZTcHdBaTZLSGEtSjVFd3RZNGdwSEFzY3ZWaHpudF…
PCSA: Stock-for-stock acquisition and $200M PIPE create a BTK-focused biotech with runway into 2029 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxNYWVrWm5neGJFZHF5MTdjcnVYNjk3eXplVUxaemRoNDQwT1FfSjJyZmZyN2tsVnE5MzFSNFc2UHRyZWJqNTAwVjVnSjdycHlDcGktZ3Y5MW1GZFREblB0RHdLRDVOMEdlaTN6Ukswd09pcWM0SE9zRFI4N0hpLTdJbTVES2xVdy16NEJBMW…
PCSA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBGa0JINE5xcklwTEktTW9maXQxdDVxSlFmd0V1Z095NmF6TS03UF9Vbm55eWxQWGd5dzI0R1RRR1pKVFFDQ0E?oc=5" target="_blank">PCSA</a> <font color="#6f6f6f">Finviz</font>…
PCSA Stock Jumps As Traders Zero In On Volatile Runway - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQcExZUVN5VkRaSFdSeFBpLTQtbmQ1RXg0OXlYWWZvM1Z0YlhuV1dWbVM4UnlibF8zRncyTldJXzdoWlVjWU1UQkgzdEMxdWF0UFRMaDRrMXJXdkh2UkYxaWJrYUhkcFJ5b184cFI5TlhyRlNHNUFZeGRseGk3NzZiZG5VOFB4Vnpic1E?oc…
PCSA Stock Rallies 10% After Hours— Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbmx2NnNrRlZNcVdReW4tV3lsTjFaR1U0MEVnbzhYSXNtTkpiU2szUXFnbHFJeG1HYmFQWDFtbTNuX0ktYW8yWC1rZVhUaDZfTmQ5UFNwNHNpQW9obF9Za2hLNV9HWWctNU5NYmRlbzd3dmNjTElZMy1GMEtSUGkxYTFpMC1kWHhSQXhwND…
PCSA — Frequently Asked Questions
What is the current share price of Processa Pharmaceuticals, Inc. (PCSA)?
As of 2026-09-19 21:16 PDT, Processa Pharmaceuticals, Inc. (PCSA) trades at $2.16 on NasdaqCM. Its 52-week range is $1.85 to $11.98.
What is the market capitalisation of PCSA?
Processa Pharmaceuticals, Inc. (PCSA) has a market capitalisation of $6.03M on NasdaqCM.
What is the P/E ratio of PCSA?
PCSA trades at a trailing price-to-earnings (P/E) ratio of 3.32. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -17.19.
Is PCSA a good stock to buy?
This page provides a data-driven analysis of Processa Pharmaceuticals, Inc. (PCSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.